- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07491952
Kontinuerlig dobbelt aspirations-teknik med Zoom-system til slagtilfælde (ADAPT 2 0)
Klinisk evaluering af kontinuerlig dobbeltaspirationsteknik med Zoom-system til apopleksi (ADAPT 2.0)
This study is designed to evaluate the effectiveness, safety and clinical performance of ADAPT 2.0, first-line aspiration neurothrombectomy with Zoom System with Continuous Dual Aspiration Technique (CDAT).
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiekontakt
- Navn: Pojai Phattanagosai
- Telefonnummer: 650-740-7703
- E-mail: pphattanagosai@Imperativecare.com
Undersøgelse Kontakt Backup
- Navn: Emma Pham
- Telefonnummer: 408-421-7684
- E-mail: epham@imperativecare.com
Studiesteder
-
-
Alabama
-
Huntsville, Alabama, Forenede Stater, 35801
- Rekruttering
- Huntsville Hospital
-
Kontakt:
- Farrar Hickey
-
Ledende efterforsker:
- R. Dana Tomalty, MD
-
-
California
-
Walnut Creek, California, Forenede Stater, 94598
- Rekruttering
- John Muir Health
-
Ledende efterforsker:
- Benjamin Yim, MD
-
Kontakt:
- Melenie Aaron
-
-
Florida
-
Tampa, Florida, Forenede Stater, 33606
- Rekruttering
- University of South Florida
-
Ledende efterforsker:
- Maxim Mokin, MD
-
Kontakt:
- Kilaun Robinson
-
-
Georgia
-
Marietta, Georgia, Forenede Stater, 30060
- Rekruttering
- Wellstar Kennestone Hospital
-
Kontakt:
- Autumn Lee
-
Ledende efterforsker:
- Ahmad Khaldi, MD
-
-
Louisiana
-
Lafayette, Louisiana, Forenede Stater, 70503
- Rekruttering
- Ochsner Clinic Foundation (Lafayette)
-
Ledende efterforsker:
- Shail Thanki, MD
-
New Orleans, Louisiana, Forenede Stater, 70121
- Rekruttering
- Ochsner Clinic Foundation
-
Ledende efterforsker:
- James Milburn, MD
-
Kontakt:
- Jessica Henry
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21201
- Rekruttering
- University of Maryland
-
Ledende efterforsker:
- Jacob Cherian, MD
-
Kontakt:
- Katie Henry
-
-
Minnesota
-
Minneapolis, Minnesota, Forenede Stater, 55407
- Rekruttering
- Allina Health
-
Kontakt:
- Emeryth Beloy
-
Ledende efterforsker:
- Collin Torok, MD
-
-
New York
-
Albany, New York, Forenede Stater, 12208
- Rekruttering
- Albany Medical College
-
Ledende efterforsker:
- Alexandra Paul, MD
-
Kontakt:
- Chelsey Large
-
Buffalo, New York, Forenede Stater, 14203
- Rekruttering
- University at Buffalo Neurosurgery
-
Ledende efterforsker:
- Jason Davies, MD
-
Kontakt:
- Ellen Carl
-
New York, New York, Forenede Stater, 10065
- Rekruttering
- Weill Cornell Medicine
-
Kontakt:
- Hanah Hwang
-
Ledende efterforsker:
- Amol Mehta, MD
-
New York, New York, Forenede Stater, 10029
- Rekruttering
- Icahn School of Medicine at Mount Sinai
-
Kontakt:
- Kevin Buttet
-
Ledende efterforsker:
- Michael T Caton, MD
-
Syracuse, New York, Forenede Stater, 13210
- Rekruttering
- SUNY Upstate Medical Center
-
Kontakt:
- Saptarshi Prachi
-
Ledende efterforsker:
- Haydn Hoffman, MD
-
The Bronx, New York, Forenede Stater, 10467
- Rekruttering
- Montefiore Medical Center
-
Kontakt:
- Genesis Liriano
-
Ledende efterforsker:
- Amanda Baker, MD
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45220
- Rekruttering
- TriHealth Good Samaritan Hospital
-
Ledende efterforsker:
- Andrew Ringer, MD
-
Kontakt:
- Mehnaaz Ali
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forenede Stater, 73104
- Rekruttering
- University of Oklahoma, Health Science Center
-
Ledende efterforsker:
- Hakeem Shakir, MD
-
Kontakt:
- Sanaa Hameed
-
-
South Carolina
-
Greenville, South Carolina, Forenede Stater, 29605
- Rekruttering
- Prisma Health - Upstate
-
Kontakt:
- Shawn Manos
-
Ledende efterforsker:
- Jan Vargas Machaj, MD
-
-
Tennessee
-
Knoxville, Tennessee, Forenede Stater, 37902
- Rekruttering
- Fort Sanders Regional Medical Center
-
Kontakt:
- Cameron Carter
-
Ledende efterforsker:
- Robert Hixson, MD
-
Memphis, Tennessee, Forenede Stater, 38120
- Rekruttering
- Semmes Murphey Foundation
-
Ledende efterforsker:
- Lucas Elijovich, MD
-
Kontakt:
- Wendell Barnett
-
-
Texas
-
Kingwood, Texas, Forenede Stater, 77339
- Rekruttering
- HCA Houston Healthcare Kingwood
-
Ledende efterforsker:
- Mohamad Ezzeldin, MD
-
Kontakt:
- Swathi Potla
-
San Antonio, Texas, Forenede Stater, 78229
- Rekruttering
- Methodist Healthcare System of San Antonio
-
Kontakt:
- Samantha Franklin
-
Ledende efterforsker:
- Lee Birnbaum, MD
-
San Antonio, Texas, Forenede Stater, 78229
- Rekruttering
- University of Texas Science Health Center at San Antonio
-
Ledende efterforsker:
- Justin Mascitelli, MD
-
Kontakt:
- Athena Lazaris-Conner
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84112
- Rekruttering
- University of Utah
-
Kontakt:
- Andrew Grandemange
-
Ledende efterforsker:
- Robert Rennert, MD
-
-
Virginia
-
Falls Church, Virginia, Forenede Stater, 22042
- Rekruttering
- Inova Fairfax Medical Campus
-
Kontakt:
- Lauren Monroe
-
Ledende efterforsker:
- James McEachern, MD
-
-
Washington
-
Spokane, Washington, Forenede Stater, 99204
- Rekruttering
- Providence Sacred Heart Medical Center and Children's Hospital
-
Kontakt:
- Kyle Kramer
-
Ledende efterforsker:
- Christopher Zylak, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Adult subjects with acute ischemic stroke secondary to large vessel occlusion (LVO) meeting the study eligibility criteria and providing written informed consent.
Beskrivelse
Inclusion Criteria:
- Subject is ≥ 18 years of age
- Subject or legally authorized representative has provided written informed consent prior to any study-specific procedures and no later than 72 hours after the index procedure
- Pre-stroke mRS 0-2
- Subject is undergoing or has undergone an aspiration thrombectomy using the Zoom System with Continuous Dual Aspiration Technique (CDAT) as the first line device within its intended use
Exclusion Criteria:
- Subjects with a life expectancy of less than 6 months
- Female subject who is known to be pregnant at time of admission
- Any intracranial hemorrhage in the qualifying head CT or MRI
- Presence of tandem internal carotid artery occlusion, multiple occlusion locations (e.g., cavernous ICA and M1, separate M2 occlusions, etc.), or occlusions in multiple territories (e.g., MCA and ACA, bilateral, etc.).
- In the opinion of the Investigator, the patient is not a suitable candidate for intervention with the Zoom System
- Subject is currently enrolled in or planned to be enrolled in any concurrent interventional study that may impact the safety or performance data collected in this study
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
ADAPT 2.0: Zoom System with Continuous Dual Aspiration Technique (CDAT)
The Zoom System is intended to be used as the first-line device and utilized within the FDA-cleared indications for use, consistent with the approved labeling and intended anatomical targets. |
Aspiration neurothrombectomy using Zoom System with Continuous Dual Aspiration Technique (CDAT)
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of patients achieving modified Thrombolysis in Cerebral Infarction (mTICI) score of ≥2c at the end of procedure, as adjudicated by independent core-lab
Tidsramme: End of procedure
|
mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches |
End of procedure
|
|
Rate of Embolization to New Territory (ENT) on final angiography at the end of the procedure by investigator assessment
Tidsramme: End of procedure
|
Embolization to New Territory (ENT), defined as the presence of new occlusions on final angiography that occur in vascular territories remote from those effected by index stroke, as assessed by the investigator |
End of procedure
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Time to achieve mTICI≥2c, defined as groin puncture to investigator assessment for mTICI≥2c
Tidsramme: Intraprocedural
|
The time from groin puncture to mTICI (modified treatment in cerebral infarction) score ≥ 2c using study device and technique. mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches |
Intraprocedural
|
|
Proportion of cases with clot ingestion, as evidenced by clot captured within the Zoom POD
Tidsramme: Intraprocedural
|
Proportion of cases with clot ingestion, as evidenced by clot captured within at least one of the Zoom PODs |
Intraprocedural
|
|
Proportion of cases with clot captured within the Zoom POD connected to the outer aspiration catheter
Tidsramme: Intraprocedural
|
Proportion of cases with clot ingestion, as evidenced by clot captured within the outer Zoom PODs |
Intraprocedural
|
|
Rate of rescue therapy
Tidsramme: Intraprocedural
|
Proportion of cases with rescue therapy, defined as unplanned use of another manufacturer's thrombectomy device, angioplasty, or stenting within the target vessel territory to achieve mTICI≥2c. |
Intraprocedural
|
|
Rate of functional independence (mRS 0-2) at 90 days
Tidsramme: 90 days post-procedure
|
Proportion of patients achieving mRS (modified Rankin Scale) ≤2 at 90 days mRS range: 0 to 6; The mRS scale ranges from 0 (no symptoms) to 5 (severe disability), with an additional category of 6 for death; higher score means worse outcome |
90 days post-procedure
|
|
Proportion of patients achieving First Pass Effect (FPE) mTICI ≥2c as adjudicated by independent core-lab
Tidsramme: Intraprocedural
|
Proportion of cases achieving First Pass Effect (FPE), defined as mTICI ≥2c after the first pass with the study device and technique as adjudicated by independent core-lab mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches |
Intraprocedural
|
|
Rate of symptomatic intracranial hemorrhage (sICH), as confirmed by imaging and independently adjudicated by medical monitor, at the 24-hour post-procedure
Tidsramme: 24-hour post-procedure
|
Independently adjudicated rate of symptomatic intracranial hemorrhage (sICH) defined as any apparently extravascular blood in the brain or within the cranium confirmed by imaging that is associated with clinical deterioration as defined by an increase of four or more points in the NIHSS at 24 hours compared to the baseline assessment, or that led to death, and was judged to be the predominant cause of a neurologic deterioration or death, per ECASS III criteria |
24-hour post-procedure
|
|
90-day all-cause mortality
Tidsramme: 90 days post-procedure
|
Rate of all-cause mortality through 90 days post-procedure |
90 days post-procedure
|
|
Rate of device-related Serious Adverse Events, independently adjudicated medical monitor
Tidsramme: Intraprocedural
|
Independently adjudicated rate of Serious Adverse Events related to study device |
Intraprocedural
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: David Fiorella, MD, Stony Brook University Hospital
- Ledende efterforsker: Shahram Majidi, MD, Icahn School of Medicine at Mount Sinai
- Ledende efterforsker: Justin Masciteli, MD, The University of Texas Health Science Center at San Antonio
- Ledende efterforsker: Maxim Mokin, MD, University of South Florida
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- ICI-2025-003
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .